Ironwood Pharmaceuticals (IRWD) Aandelenoverzicht
Ironwood Pharmaceuticals, Inc. is een biotechnologiebedrijf dat zich richt op de ontwikkeling en commercialisering van therapieën voor gastro-intestinale (GI) en zeldzame ziekten in de Verenigde Staten en daarbuiten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 3/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
IRWD Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ironwood Pharmaceuticals, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$4.32 |
| 52 Week Hoogtepunt | US$5.78 |
| 52 Week Laag | US$0.99 |
| Bèta | 0.21 |
| 1 maand verandering | 2.61% |
| 3 maanden verandering | 17.71% |
| 1 Jaar Verandering | 296.33% |
| 3 jaar verandering | -55.74% |
| 5 jaar verandering | -67.37% |
| Verandering sinds IPO | -62.92% |
Recent nieuws en updates
Narratiefupdate • Aug 07
IRWD: Pediatric Expansion And 2026 Revenue Outlook Will Support Future Upside
Analysts have trimmed their price target on Ironwood Pharmaceuticals from $11.00 to $10.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E that remain broadly consistent with prior estimates. What’s in the News for Ironwood Pharmaceuticals Ironwood Pharmaceuticals revised its 2026 earnings guidance, with total revenue now expected in a range of $460 million to $485 million, compared with prior guidance of $450 million to $475 million.Narratiefupdate • Jul 21
IRWD: Pediatric Approval And 2026 Outlook Will Support Future Upside
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $10.00 to $11.00, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E to support the new price target. What’s in the News for Ironwood Pharmaceuticals The U.S. FDA approved an expanded LINZESS (linaclotide) indication for pediatric patients 2 years and older with functional constipation, making it the only FDA approved prescription therapy specifically for pediatric functional constipation, according to company disclosures.Recent updates
Narratiefupdate • Aug 07
IRWD: Pediatric Expansion And 2026 Revenue Outlook Will Support Future Upside
Analysts have trimmed their price target on Ironwood Pharmaceuticals from $11.00 to $10.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E that remain broadly consistent with prior estimates. What’s in the News for Ironwood Pharmaceuticals Ironwood Pharmaceuticals revised its 2026 earnings guidance, with total revenue now expected in a range of $460 million to $485 million, compared with prior guidance of $450 million to $475 million.Narratiefupdate • Jul 21
IRWD: Pediatric Approval And 2026 Outlook Will Support Future Upside
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $10.00 to $11.00, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E to support the new price target. What’s in the News for Ironwood Pharmaceuticals The U.S. FDA approved an expanded LINZESS (linaclotide) indication for pediatric patients 2 years and older with functional constipation, making it the only FDA approved prescription therapy specifically for pediatric functional constipation, according to company disclosures.Seeking Alpha • Jul 13
Ironwood: Linzess Buys Time, But Apraglutide's rNPV Doesn't Close The Gap
Summary Ironwood Pharmaceuticals (IRWD) faces a looming Linzess patent cliff in 2029, with generics poised to erode its main revenue stream. Apraglutide, acquired for $1B, is unlikely to fully offset Linzess losses due to mixed Phase 3 data, regulatory delays, and a small addressable market. Apraglutide’s risk-adjusted NPV is estimated at $461M, well below IRWD’s enterprise value, and further delays could reduce this value significantly. I initiate coverage with a cautious Hold, as IRWD appears cheap but justified by limited pipeline prospects and significant execution risks. Read the full article on Seeking Alpha
Narratiefupdate • Jul 06
IRWD: Expanded Pediatric Use And Earnings Outlook Will Drive Upside Potential
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $4.85 to $6.10. This change reflects updated assumptions on the discount rate, revenue growth, profit margin, and future P/E levels.Narratiefupdate • Jun 22
IRWD: Expanded Constipation Indication And 2026 Outlook Will Support Future Upside
Analysts have modestly revised their price target for Ironwood Pharmaceuticals to $10.00, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E. These revisions leave their fair value estimate unchanged at $10.00.
Narratiefupdate • Jun 08
IRWD: Pediatric Expansion And Stable Guidance Will Support Future Upside Potential
Analysts have adjusted their $ price target on Ironwood Pharmaceuticals, reflecting updated assumptions for discount rate, revenue growth, profit margins, and future P/E, and are now framing the stock's valuation through a more measured growth outlook. What's in the News The U.S. FDA approved LINZESS (linaclotide) for functional constipation in pediatric patients 2 to 5 years old, expanding the prior indication that started at age 6 and keeping LINZESS as the only FDA approved prescription therapy for pediatric functional constipation, according to the company.Narratiefupdate • May 25
IRWD: Maintained 2026 Revenue Outlook Will Support Long Term Cash Flows
Analysts have kept their price target for Ironwood Pharmaceuticals steady at $10.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that they view as better aligned with the company’s current risk and earnings profile. What's in the News Chief Financial Officer Gregory Martini plans to resign effective May 15, 2026.Analyse-artikel • May 11
Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
A week ago, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) came out with a strong set of quarterly numbers that could...Narratiefupdate • May 01
IRWD: Earnings Outlook And Trial Updates Will Limit Future Share Upside
Analysts have slightly adjusted their price target on Ironwood Pharmaceuticals, citing updated assumptions for discount rate, revenue growth, profit margins, and future P/E, while keeping their fair value estimate broadly unchanged at $3.70. What's in the News Ironwood plans to present data from the LANDMARK survey at the 2026 Digestive Disease Week meeting in Chicago, highlighting healthcare professional views on the burden of total parenteral nutrition for short bowel syndrome and preferred attributes for new therapies that reduce dependence on parenteral support (company announcement).Narratiefupdate • Apr 17
IRWD: Extended Revenue Guidance And Margin Assumptions Will Restrain Future Upside
Analysts have slightly adjusted their price target on Ironwood Pharmaceuticals, reflecting small tweaks to inputs such as discount rate, revenue growth assumptions, profit margin outlook and the future P/E multiple, while keeping their overall fair value estimate steady at $3.70. What's in the News Ironwood Pharmaceuticals reiterated its earnings guidance for 2026, stating that total revenue is expected to be in the range of $450 million to $475 million.Narratiefupdate • Apr 02
IRWD: Multi Year Revenue Guidance And Margin Assumptions Will Shape Outlook
Analysts have raised their price target on Ironwood Pharmaceuticals by $3, reflecting updated assumptions around fair value, a lower discount rate, higher projected revenue growth, a materially stronger profit margin outlook, and a reduced future P/E multiple. What's in the News Ironwood Pharmaceuticals reiterated earnings guidance for 2026, with total revenue expected in the range of $450 million to $475 million (company guidance).Narratiefupdate • Mar 19
IRWD: Reinforced 2026 Guidance And Legal Resolution Will Support Future Cash Flows
Analysts have modestly adjusted their price target on Ironwood Pharmaceuticals, now reflecting a $10.00 fair value that aligns with updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Ironwood Pharmaceuticals reiterated earnings guidance for 2026, with total revenue expected in a range of $450 million to $475 million.Narratiefupdate • Mar 05
IRWD: Index Inclusion And Reinforced Guidance Will Support Future Cash Flows
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $8.00 to $10.00, citing updated assumptions for revenue growth, profit margins, and future P/E expectations built into their models. What's in the News Ironwood Pharmaceuticals reiterated its 2026 earnings guidance, with total revenue expected in a range of $450 million to $475 million.Narratiefupdate • Feb 19
IRWD: Medicare Pricing Clarity Will Support Future Cash Flows And Optionality
Analysts have raised their price target on Ironwood Pharmaceuticals to $3.80 from $1.70, citing clearer visibility on future Linzess pricing after the Centers for Medicare and Medicaid Services set a negotiated $136 Medicare price for a 30 day supply. They view this as supportive of the company as it reviews alternatives.Narratiefupdate • Feb 05
IRWD: Medicare Pricing Clarity And Revenue Outlook Will Shape Balanced Share Prospects
Ironwood Pharmaceuticals' analyst price target has moved higher, with the fair value estimate shifting from about US$2.50 to roughly US$4.85. Analysts cite updated revenue growth, profit margin and future P/E assumptions, along with recent Medicare pricing clarity for Linzess, as key drivers of their revised view.Narratiefupdate • Jan 22
IRWD: Medicare Pricing Clarity Will Support Future Earnings And Deal Optionality
Narrative Update Overview Analysts have raised their price target for Ironwood Pharmaceuticals to US$3.80 from US$1.70, citing clearer visibility on future Linzess Medicare pricing following the recent Inflation Reduction Act negotiation outcomes. Analyst Commentary Bullish analysts are highlighting the recent Medicare pricing outcome for Linzess as an important input into their updated view on Ironwood Pharmaceuticals.Narratiefupdate • Jan 07
IRWD: Medicare Price Certainty Will Support Stronger Earnings And Optionality
Analysts have lifted their 12 month fair value estimate for Ironwood Pharmaceuticals from $3.80 to $8.00, citing clearer Medicare pricing for Linzess and what they view as a stronger setup as the company reviews potential alternatives. Analyst Commentary Recent research has focused on how clearer Medicare pricing for Linzess could affect Ironwood Pharmaceuticals' valuation and options review.Analyse-artikel • Jan 06
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have continued their recent momentum with a 32% gain in the last...Narratiefupdate • Dec 13
IRWD: Medicare Pricing Clarity Will Support More Predictable Earnings And Balanced Outlook
Analysts have lifted their price target on Ironwood Pharmaceuticals to $3.80 from $1.70, citing improved visibility on Linzess Medicare pricing that supports higher long term profitability. This, they say, justifies a lower discount rate, a more stable revenue outlook, and a richer fair value assessment.Narratiefupdate • Nov 28
IRWD: Future Share Price Could Weaken Amid Upcoming Medicare Price Cuts
Analysts have increased their price target for Ironwood Pharmaceuticals to $3.80 from $1.70. They cite greater clarity on future Medicare pricing and strategic opportunities following recent policy announcements.Narratiefupdate • Nov 13
IRWD: Future Expectations May Not Justify Recent Share Price Levels
Analysts have raised their price target for Ironwood Pharmaceuticals from $0.95 to $1.85. They cited improved revenue growth projections, a reduced discount rate, and a substantial increase in expected profit margins.Analyse-artikel • Nov 12
Need To Know: Analysts Are Much More Bullish On Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenues
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders will have a reason to smile today, with the analysts making...Analyse-artikel • Nov 06
There's No Escaping Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Muted Revenues Despite A 39% Share Price Rise
Despite an already strong run, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have been powering on, with a gain...Narratiefupdate • Oct 29
Worsening Revenue Outlook Will Limit Upside Despite Improving Profit Margins
Analysts have lowered their price target for Ironwood Pharmaceuticals from $0.95 to $0.95, citing reduced revenue growth expectations. This has been offset by improved profit margins and a lower discount rate.Analyse-artikel • Sep 10
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 33% But Its Business Prospects Need A Lift Too
Despite an already strong run, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have been powering on, with a gain...Analyse-artikel • Jun 25
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Held Back By Insufficient Growth Even After Shares Climb 28%
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders are no doubt pleased to see that the share price has...Analyse-artikel • Dec 21
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders would be excited to see that the share price has had a...Analyse-artikel • Oct 24
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 1.6x Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) is...
Nieuw narratief • Sep 17
LINZESS And Apraglutide Set To Power Through Market Challenges With Strong Growth Prospects
LINZESS prescription growth indicates strong market acceptance, potentially increasing revenue as it gains market share.Analyse-artikel • Aug 16
Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There
The market seemed underwhelmed by the solid earnings posted by Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) recently...Analyse-artikel • Jun 27
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 2.4x Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) is...Seeking Alpha • Jun 20
Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Summary Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024. The global primary biliary cholangitis therapeutics market size is projected to reach $1.4 billion by 2032. NDA filing and other regulatory filings across the globe of apraglutide for the treatment of patients with short bowel syndrome who are dependent on parenteral support. Ironwood Pharmaceuticals had cash and cash equivalents of $121.5 million as of March 31st of 2024; Enough cash to fund its operations for at least the next 12 months. Read the full article on Seeking AlphaRendement voor aandeelhouders
| IRWD | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 4.1% | 4.9% | 0.09% |
| 1Y | 296.3% | 41.3% | 19.0% |
Rendement versus industrie: IRWD overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 41.3 % opleverde.
Rendement versus markt: IRWD overtrof de US markt, die het afgelopen jaar een rendement opleverde van 19 %.
Prijsvolatiliteit
| IRWD volatility | |
|---|---|
| IRWD Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: IRWD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van IRWD is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1998 | 100 | Tom McCourt | ironwoodpharma.com |
Ironwood Pharmaceuticals, Inc., een biotechnologiebedrijf, richt zich op de ontwikkeling en commercialisering van therapieën voor gastro-intestinale (GI) en zeldzame ziekten in de Verenigde Staten en internationaal. Het verkoopt linaclotide, een agonist van guanylaatcyclase type-C (GC-C) voor de behandeling van volwassenen die lijden aan het prikkelbare darmsyndroom met constipatie of chronische idiopathische constipatie, evenals voor pediatrische patiënten die lijden aan functionele constipatie onder de namen LINZESS en CONSTELLA. Het bedrijf ontwikkelt ook IW-3300, een GC-C-agonist voor de behandeling van viscerale pijnaandoeningen, waaronder interstitiële cystitis/bladpijnsyndroom en endometriose; en apraglutide, een synthetisch peptide langwerkend analoog van glucagon-like peptide-2 voor patiënten met het korte darmsyndroom die afhankelijk zijn van parenterale ondersteuning, evenals voor acute graft versus host ziekte.
Ironwood Pharmaceuticals, Inc. Samenvatting
| IRWD fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$710.53m |
| Inkomsten(TTM) | US$129.87m |
| Inkomsten(TTM) | US$389.32m |
5.5x
Koers/Winstverhouding1.8x
P/S-verhoudingIs IRWD overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| IRWD resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$389.32m |
| Kosten van inkomsten | US$88.69m |
| Brutowinst | US$300.62m |
| Overige uitgaven | US$170.76m |
| Inkomsten | US$129.87m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.79 |
| Brutomarge | 77.22% |
| Nettowinstmarge | 33.36% |
| Schuld/Eigen Vermogen Verhouding | -237.9% |
Hoe presteerde IRWD op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/12 00:56 |
| Aandelenkoers aan het einde van de dag | 2026/08/12 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Ironwood Pharmaceuticals, Inc. wordt gevolgd door 26 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Geoffrey Meacham | Barclays |
| Patrick Trucchio | Berenberg |
| David Maris | BMO Capital Markets Equity Research |